In the time before ledipasvir was available, clinical trials with sofosbuvir-based regimens (such as sofosbuvir + ribavirin, or sofosbuvir + interferon + ribavirin) resulted in generally high rates of SVR12. However, there have been cases where HCV was not cured in people who used those sofosbuvir-containing regimens.
Researchers enrolled 51 people who were not cured with sofosbuvir-based regimens and retreated them with the potent combination of ledipasvir + sofosbuvir for 12 weeks.
The average profile of participants at the start of the study was as follows:
Out of 51 participants, 50 (98%) developed an SVR12.
In one participant who relapsed, technicians discovered HCV genotype 3a infection. Ledipasvir + sofosbuvir are not highly effective against this strain of HCV.
Wyles DL, Pockros PJ, Yang JC, et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract 235.
No comments have been made.
|Gene Therapy in HIV Cure Research|
|Making HIV -- and Bias -- 'Part of the Party' to Strengthen Our Response to the Epidemic|
|One Doc's Advice for Caring for Elderly Patients With HIV|
|Bias Is Everywhere: Uncovering HIV Prejudice to Improve Service Delivery|
|Who Tends to Gain Weight With HIV Treatment?|